Concepedia

Author

Zbigniew Rudzki

South Australia PathologyORCID

Also Known As

Dr. Zbigniew Rudzki, Z Rudzki, Z. RUDZKI, Z. Rudzki, Zbigniew Barney Rudzki, Zbigniew RUDZKI, Zbigniew Rudzki

135

Publications

5.1K

Citations

24

H-Index

83

Concepts

All Affiliations

South Australia PathologyJagiellonian UniversityNovartis (Australia)The Royal Melbourne HospitalHeartlands Hospital
ZR

About

Zbigniew Rudzki is an author at South Australia Pathology specializing in medicine, pathology, and hematology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

25

651

2

Health Sciences

7

7

246

3

Natural Sciences

2

2

50

4

Public Health

2

2

45

5

Biochemistry

2

2

28

Zbigniew Rudzki

×

51

Publications

4.7K

Citations

23

H-Index

YearCitations

Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia

Timothy P. Hughes, Jaspal Kaeda, Susan Branford,

New England Journal of Medicine

2003

1.2K

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh,

Blood

2003

766

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh,

Blood

2002

657

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C.P. Cross,

Blood

2008

386

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

Victoria Weston, Ceri Oldreive, Anna Skowrońska,

Blood

2010

302

Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase

Susan Branford, Zbigniew Rudzki, Andrew Harper,

Leukemia

2003

157

BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria

Susan Branford, John F. Seymour, Andrew Grigg,

Clinical Cancer Research

2007

139

MUTATIONS IN A SUBGROUP OF PATIENTS WITH MILD HAEMOPHILIA A AND A FAMILIAL DISCREPANCY BETWEEN THE ONE‐STAGE AND TWO‐STAGE FACTOR VIII:C METHODS

Zbigniew Rudzki, Elizabeth M. Duncan, G. Casey,

British Journal of Haematology

1996

87

NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma

Helen Parry, Tom H. Stevens, Ceri Oldreive,

Oncotarget

2016

61

Generalized crystal-storing histiocytosis as a presentation of multiple myeloma: a case with a possible pro-aggregation defect in the immunoglobulin heavy chain

Bolesław Papla, Pawel Sp�lnik, Ewa Rzenno,

Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin

2003

52

Page 1